文章基本信息

标题：Vaginal mesh – the controversy
本地全文：下载
作者：Joanna M. Togami ; Elizabeth Brown ; J. Christian Winters 等
期刊名称：F1000 Biology Reports
电子版ISSN：2051-7599
出版年度：2012
卷号：4
DOI：10.3410/M4-21
语种：English
出版社：Faculty of 1000 Ltd
摘要：Pelvic organ prolapse is a condition that can cause significant symptoms that affect a woman's quality of life. It is the result of defects in the supporting structures of the vagina and, depending on the location and size, can alter the functions of the organs contained within the female pelvis. Approximately 11% of women will undergo surgical intervention for their prolapse or for incontinence in their lifetime. Unfortunately, one third of these will require reoperation for failed procedures. Pelvic floor surgeons have sought to improve these outcomes. Based largely on the success of midurethral slings (MUS), transvaginal mesh has been implanted, and commercial kits developed with the intent of improving these outcomes. In 2008, the Food and Drug Administration (FDA) issued a Public Health Notification in response to possible increased adverse events associated with the use of mesh compared to traditional repairs. The 2011 update required that further study be conducted for the use of transvaginal mesh. In this article, we wish to discuss the background of mesh use and the evolution of the public health warnings, and focus on future prospects.